Bryce Point Capital LLC Makes New $1.89 Million Investment in Natera, Inc. (NASDAQ:NTRA)

Bryce Point Capital LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 11,939 shares of the medical research company's stock, valued at approximately $1,890,000. Natera makes up 0.5% of Bryce Point Capital LLC's holdings, making the stock its 18th biggest holding.

Other large investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Natera by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after buying an additional 142,201 shares during the period. HighPoint Advisor Group LLC bought a new stake in Natera during the fourth quarter worth about $258,000. Franklin Resources Inc. raised its stake in shares of Natera by 40.0% in the fourth quarter. Franklin Resources Inc. now owns 1,538,875 shares of the medical research company's stock valued at $243,604,000 after acquiring an additional 439,540 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Natera by 15.7% in the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after acquiring an additional 439,778 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in Natera by 26.9% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 6,594 shares of the medical research company's stock worth $1,044,000 after acquiring an additional 1,396 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Remove Ads

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 24,861 shares of the business's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,101,319.17. Following the sale, the insider now owns 140,684 shares of the company's stock, valued at $23,208,639.48. The trade was a 15.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John Fesko sold 663 shares of the firm's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock valued at $51,603,664 over the last three months. Company insiders own 7.60% of the company's stock.

Analyst Ratings Changes

NTRA has been the topic of a number of recent analyst reports. Robert W. Baird boosted their price objective on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Barclays began coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price for the company. Piper Sandler increased their price target on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target for the company. Finally, Sanford C. Bernstein increased their price objective on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.12.

Natera Stock Up 1.0 %

NASDAQ NTRA traded up $1.35 during trading hours on Monday, reaching $135.22. 883,155 shares of the company's stock were exchanged, compared to its average volume of 1,376,026. The company has a market capitalization of $18.28 billion, a price-to-earnings ratio of -76.77 and a beta of 1.80. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company's 50-day moving average is $156.81 and its two-hundred day moving average is $151.57.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.